1,341 Views

DIABETES CANADA

CLINICAL CARE AND EDUCATION

NURSING

DIABETES

SIMULTANEOUS INTERPRETATION

PHARMACIST

CLINICAL PRACTICE GUIDELINES UPDATE: PART 1 (TYPE 1 DIABETES ACROSS THE LIFESPAN; ORGANIZATION OF CARE; HYPOGLYCEMIA; DISSEMINATION & IMPLEMENTATION OF THE GUIDELINES) / MISE À JOUR DES LIGNES DIRECTRICES DE PRATIQUES CLINIQUES - PREMIÈRE PARTIE : DIABÈTE DE TYPE 1 TOUT AU LONG DE LA VIE; ORGANISATION DES SOINS; HYPOGLYCÉMIE; DIFFUSION ET IMPLANTATION DES LIGNES DIRECTRICES

CLINICAL PRACTICE GUIDELINES UPDATE: PART 1 (TYPE 1 DIABETES ACROSS THE LIFESPAN; ORGANIZATION OF CARE; HYPOGLYCEMIA; DISSEMINATION & IMPLEMENTATION OF THE GUIDELINES) /MISE À JOUR DES LIGNES DIRECTRICES DE PRATIQUES CLINIQUES - PREMIÈRE PARTIE : DIABÈTE DE TYPE 1 TOUT AU LONG DE LA VIE; ORGANISATION DES SOINS; HYPOGLYCÉMIE; DIFFUSION ET IMPLANTATION DES LIGNES DIRECTRICES (DC-004)

Thursday, October 26, 2023

08:30 – 09:30 EST

Location: Palais, 517BC

Chair(s)

Harpreet S. Bajaj, MD, MPH, ECNU, FACE (he/him/his)

Endocrinologist & Medical Director, Endocrine and Metabolic Research
LMC Healthcare
Diabetes Canada

Presenter(s)

Jeremy Gilbert, MD,FRCPC

MD, FRCPC
Sunnybrook Health Sciences Centre, University of Toronto
University of Toronto
Ilana Halperin, MD, MSc (she/her/hers)

Endocrinologist
Sunnybrook and University of Toronto
University of Toronto
Iliana C. Lega, MD, MSc, FRCPC (she/her/hers)

Physician
Women's College Hospital
University of Toronto
Barbara MacDonald, RN, MS-DEDM, CDE (she/her/hers)

Co-founder and Diabetes Consultant
IDEA Diabetes Inc.
Brandy Wicklow, MD, MSc(epi), FRCPC

Associate Professor, Head Section of Pediatric Endocrinology, Department of Pediatrics and Child Health, Winnipeg, MB
University of Manitoba
University of Manitoba

Disclosure(s):

Harpreet S. Bajaj, MD, MPH, ECNU, FACE: Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Anji: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); AstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Boehringer Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eli Lilly: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kowa: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Jeremy Gilbert, MD,FRCPC: Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Speaker/Honoraria (Ongoing); HLS Therapeutics: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Phizer: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Ilana Halperin, MD, MSc: Abbott Diabetes: Consultant/Advisory Board (Ongoing); Dexcom Canada: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Iliana C. Lega, MD, MSc, FRCPC: No financial relationships to disclose

Barbara MacDonald, RN, MS-DEDM, CDE: BC Aboriginal Diabetes Conference: Speaker/Honoraria (Terminated); BC First Nations Health Authority: Consultant/Advisory Board (Ongoing); IDEA Diabetes Inc.: Employment (Ongoing); National Indigenous Diabetes Association: Consultant/Advisory Board (Ongoing)

Brandy Wicklow, MD, MSc(epi), FRCPC: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

Dissemination & Implementation: Evaluate the current role of the dissemination and implementation committee for the CPGs and discuss potential future opportunities
Organization of Care: Describe the process to ensure the updated chapter provides the foundational principles of diabetes care to meet the needs of all people with diabetes from coast to coast to coast
Type 1 diabetes across the lifespan: Explain the landscape of type 1 diabetes in Canada, identify key care components, and describe the impetus and implications of a new guideline for this area of care